Vectura Group

Vectura Group (VEC)

Vectura Group News, Fundamentals and Discussion on:

Vectura Group page on Interactive Investor
Vectura Group page on Financial Times
Vectura Group page on ADVFN
Vectura Group page on London South East
Vectura Group page on Bloomberg Markets
Vectura Group page on This is Money
Vectura Group page on Motley Fool
Vectura Group page on Proactive Investors
Ayondo
Ayondo

Vectura Group RNS, News and Media

Headline

17 Nov 2017
Vectura Group plc - Vectura Group announces Transaction in Own Sharesfrom Interactive Investor
17 Nov 2017
RNS press release - Vectura Group announces Transaction in Own Shares from Proactive Investors
16 Nov 2017
Vectura Group plc - Vectura Group announces Transaction in Own Sharesfrom Interactive Investor
16 Nov 2017
RNS press release - Vectura Group announces Transaction in Own Shares from Proactive Investors
15 Nov 2017
Vectura Group plc - Holdings in Companyfrom Interactive Investor
15 Nov 2017
Vectura Group plc - Vectura Group announces Transaction in Own Sharesfrom Interactive Investor
15 Nov 2017
RNS press release - Vectura Group announces Transaction in Own Shares from Proactive Investors
15 Nov 2017
RNS press release - Holdings in Company from Proactive Investors
14 Nov 2017
Vectura Group plc - Share buyback and cancellationfrom Interactive Investor
14 Nov 2017
RNS press release - Share buyback and cancellation from Proactive Investors
9 Nov 2017
Vectura Group plc - Director/PDMR Shareholdingfrom Interactive Investor
9 Nov 2017
Vectura Group plc - Hikma statement on ANDA for generic Advair(VR315)from Interactive Investor
9 Nov 2017
RNS press release - Hikma statement on ANDA for generic Advair(VR315) from Proactive Investors
9 Nov 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
1 Nov 2017
Vectura Group plc - Voting Rights and Capitalfrom Interactive Investor
1 Nov 2017
RNS press release - Voting Rights and Capital from Proactive Investors
24 Oct 2017
Vectura Group plc - Ultibro Breezhaler delivers strong growth in Q3from Interactive Investor
24 Oct 2017
RNS press release - Ultibro Breezhaler delivers strong growth in Q3 from Proactive Investors
19 Oct 2017
Vectura Group plc - Launch of SeebriT Neohaler® in the USfrom Interactive Investor
19 Oct 2017
RNS press release - Launch of SeebriT Neohaler® in the US from Proactive Investors
10 Oct 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
4 Oct 2017
RNS press release - Vectura Group Employee Benefit Trust from Proactive Investors
4 Oct 2017
RNS press release - Positive flutiform k-haler regulatory progress from Proactive Investors
3 Oct 2017
RNS press release - Voting Rights and Capital from Proactive Investors
22 Sep 2017
RNS press release - Holding(s) in Company from Proactive Investors
18 Sep 2017
RNS press release - Holding(s) in Company from Proactive Investors
13 Sep 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
12 Sep 2017
RNS press release - Mundipharma presents positive findings at ERS 2017 from Proactive Investors
12 Sep 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
8 Sep 2017
RNS press release - Director's Share Purchase - Replacement from Proactive Investors
8 Sep 2017
RNS press release - Director's Share Purchase from Proactive Investors
7 Sep 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
6 Sep 2017
RNS press release - Vectura announces VR410 agreement with Pulmatrix from Proactive Investors
6 Sep 2017
RNS press release - Interim Results 2017 from Proactive Investors
6 Sep 2017
News - Analyst thinks Vectura share price drop may not just be due to bigger pre-tax loss from Proactive Investors
1 Sep 2017
RNS press release - Voting Rights and Capital from Proactive Investors
30 Aug 2017
RNS press release - Holding(s) in Company from Proactive Investors
17 Aug 2017
RNS press release - Hikma statement on generic Advair Diskus® (VR315) from Proactive Investors
16 Aug 2017
RNS press release - Global development agreement with Dynavax from Proactive Investors
16 Aug 2017
News - Vectura Group to hook up with Dynavax to develop cancer treatment from Proactive Investors
7 Aug 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
1 Aug 2017
RNS press release - Voting Rights and Capital from Proactive Investors
27 Jul 2017
RNS press release - Notice of Interim Results from Proactive Investors
10 Jul 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
3 Jul 2017
RNS press release - VOTING RIGHTS AND CAPITAL from Proactive Investors
28 Jun 2017
RNS press release - Vectura host Capital Markets Event today in London from Proactive Investors
28 Jun 2017
RNS press release - New development and licence agreement from Proactive Investors
16 Jun 2017
RNS press release - Holding(s) in Company from Proactive Investors
12 Jun 2017
RNS press release - Holdings in Company from Proactive Investors
6 Jun 2017
RNS press release - Holdings in Company from Proactive Investors
1 Jun 2017
RNS press release - VOTING RIGHTS AND CAPITAL from Proactive Investors
26 May 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
26 May 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
25 May 2017
RNS press release - Result of AGM from Proactive Investors
22 May 2017
RNS press release - VR942 Positive Phase I data to be presented at ATS from Proactive Investors
17 May 2017
RNS press release - Notice of Capital Markets Event from Proactive Investors
11 May 2017
RNS press release - Status update of ANDA for generic Advair Diskus® from Proactive Investors
8 May 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
2 May 2017
RNS press release - VOTING RIGHTS AND CAPITAL from Proactive Investors
24 Apr 2017
RNS press release - Report and Accounts ended 31 Dec 2016 and AGM 2017 from Proactive Investors

Vectura Group Charted

Vectura Group Discussion on Interactive Investor

Re: Glaxo FDA approval to exstend Elli... by sadoldsod

  Thu, 23 Nov 2017 16:34:00 GMT
THANKS.
By sadoldsod

Re: Glaxo FDA approval to exstend Ellipta by d gaser

  Thu, 23 Nov 2017 15:03:00 GMT
Sorry I left a link on my last post plus it didn't read correctly.

It appears GlaxoSmithKline along with its partner Innoviva have applied for a FDA application for the approval to expand Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for an expanded indication, but how can they do this, when VEC have all ready initiated court proceeding against them .

www.iii.co.uk/research/LSE:VEC/news/item/2052828/vectura-initiates-legal-proceedings-against-gsk?context=LSE:VEC
 
Vectura initiates legal proceedings against GSK relating to option-to-licence patent agreement and confirms 2016 revenue guidance
 
This announcement includes inside information
 
Chippenham, UK - 27 July 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, announces that it has received formal notification from GlaxoSmithKline ('GSK') that GSK does not wish to exercise the option to take a license to any additional patents under the patent licence and option agreement with Vectura dated 5th August 2010 for GSK's Breo® Ellipta®/Relvar® Ellipta®, Anoro® Ellipta® and Incruse® Ellipta®  products (the "Ellipta® products"). 
 .
BE HAPPY
DAVE

Glaxo Smith Kline have announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration on Thursday, for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for an expanded indication. The FTSE 100 drugmaker said that indication was for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease. It said approval of the sNDA would mean FF/UMEC/VI could be used by physicians to treat a wider population of patients with COPD, who were at risk of an exacerbation and required triple therapy see link below
www.gsk.com/en-gb/media/press-releases/gsk-submits-landmark-impact-data-to-us-regulatory-authority-to-support-expanded-label-for-trelegy-ellipta/
By d gaser

Re: Glaxo FDA approval to exstend Ellipta by sadoldsod

  Thu, 23 Nov 2017 14:28:00 GMT
Bad news? Can you explain effects of this on VEC.
CHEERS MARTIN
By sadoldsod

Glaxo FDA approval to exstend Ellipta by d gaser

  Thu, 23 Nov 2017 13:14:00 GMT
This news it appears to exclude VAC as it states GlaxoSmithKline, along with its partner Innoviva.

FDA application for approval to expand Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for an expanded indication.

Glaxo Smith Kline have announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration on Thursday, for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for an expanded indication. The FTSE 100 drugmaker said that indication was for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease. It said approval of the sNDA would mean FF/UMEC/VI could be used by physicians to treat a wider population of patients with COPD, who were at risk of an exacerbation and required triple therapy
BE HAPPY
DAVE .
By d gaser

Re: Re: by raptor66

  Mon, 20 Nov 2017 13:44:00 GMT
Imo I have never seen any buybacks which have done good to any Co's sp for the benefit of shareholders, I believe only the management reap the rewards from this.
This money could have been spent on further R&D or on a new project to bring additional treatment to the market.

Or ~1.92p special dividend would have been nice for the long suffering shareholders??
By raptor66

Re: Re: by d gaser

  Mon, 20 Nov 2017 11:29:00 GMT
VEC would have done much better had they used the cash to buy out another company that was all ready self sufficient .at least that would have given us a return on their capital , buy this way, we might as well thrown the cash down a drain, as we are not going to profit from it any way soon .
BE Happy
Dave
By d gaser

Re: Re: by raptor66

  Thu, 16 Nov 2017 11:36:00 GMT
Buy backs may not be to improve VEC's sp or sway the current sentiment. It could be to reduce the cash built up to deter a predator to go for a takeover to get the hand on the cash pile??
Remember VEC reduced their cash surplus by paying cash (~70m) for some of the SKP shares during the merger of the two companies.
By raptor66

Re: Re: by sadoldsod

  Thu, 16 Nov 2017 08:29:00 GMT
Agree buy back not working looks a good bet to short at moment.
By sadoldsod

Re: by dave297

  Thu, 16 Nov 2017 07:42:00 GMT
Yesterdays RNS that Invesco have increased their substantial holding by a further 1.5 mill shares (approx) tofgether our buy backs of 320k have not,as yet improved our SP.Sentiment is currently so poor that our brokers could probably buy the balance of the £15mill shares over the next week or so without any affect on our SP.Having started buying 120k & increased to 300k yesterday it will be interesting to see if they increase the total amount bought again today.
we need some great news to break the cycle ,although my cycle is well & truly broken here !
By dave297

Re: £15mill share buy backs by d gaser

  Tue, 14 Nov 2017 15:39:00 GMT
This smacks of panic in the board ,especially after such a massif drop in VEC, S/P over the past 6 months .I should think there is a very big overhang of unwanted shares right now ,which the MM are unable to shift ,that means a soft market in VEC shares could persist for many months if they don't buy them back , that overhang would also hit their own share bonus allotment scheme at the end of year, if the S/P hasn't risen by what ever percentage is required in their bonus package .


How ever I for one am pleased the board have decided to reduce, or obliterate this overhang, as that will give the market makers & the market confidence in VEC as a company, and hopefully we will then see our S/P move north above the £1 mark again ,it would also help, if they could release a good news story now, as that would help push the S/P Further north again .
just my opinion
BE HAPPY
DAVE
By d gaser

Re: £15mill share buy backs by Andy Reilly

  Tue, 14 Nov 2017 14:18:00 GMT
r66 - I must say that share buy backs have never lived up to the hype, and the effect is usually very marginal, so we are left waiting for something more positive to lift the SP.... ATB AR
By Andy Reilly

Re: £15mill share buy backs by raptor66

  Tue, 14 Nov 2017 12:04:00 GMT
The total number of ordinary shares in the Company (VEC) with voting rights is 679, 354,709.

£15m (2.4%) buyback is not much, I guess this and with the recent Directors buys the management are trying to sway the current sentiment.

Personally, buybacks do not do any thing to company's sp other than slightly better EPS.
By raptor66

£15mill share buy backs by dave297

  Tue, 14 Nov 2017 07:25:00 GMT
Unlikely to have much impact as will only result in the cancellation of £16-£17 mill shares at our current SP & suggests that our Board cannot think of a better use for our £15mill-although should give confidence that we are financially sound.
By dave297

Re: Vec sale by Andy Reilly

  Fri, 10 Nov 2017 12:05:00 GMT
r66 - well brokes are there to do a job, and when it suits them they will 'big a share up'! I am always dubious abut brokers notes, particularly as they are paid to say stuff by the company they represent... if only there view did have a real impact! Anyway, best of luck - AR
By Andy Reilly

Re: Vec sale by raptor66

  Fri, 10 Nov 2017 11:21:00 GMT
Andy, this is a same broker suggested 264p for VEC at the time of the merger. I have noted each time VEC sp crashes this broker revises down the sp. It would be nice if they give some timeline to their suggestions??
By raptor66